Illumina

Truveta is a healthcare data platform that collaborates with physicians, life science researchers, and various stakeholders in the healthcare community. The company focuses on aggregating and de-identifying medical records from its partner organizations, enabling it to provide valuable insights into treatment outcomes and health factors. Initially concentrating on COVID-19, Truveta aims to accelerate medical research, empower clinicians with expert knowledge, and assist families in making informed healthcare decisions. By connecting treatments with results, Truveta enhances the understanding of health data to drive improvements in patient care.

Cache is a biotechnology company focused on developing a groundbreaking wet operating system designed for the storage, access, and computation of biomolecules at scale. By ensuring the integrity and fidelity of nucleic acids from various sources, Cache enables researchers and partners to accelerate molecular pathology research and gain insights into life sciences. This innovative approach facilitates the analysis of biomolecules, thereby unlocking new precision medicine applications and enhancing the capacity for understanding biological data. Ultimately, Cache aims to make both digital and biological data universally accessible and sustainable, eliminating the need for data deletion or disposal.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which integrates computational biology, wet lab techniques, and automation. This innovative approach leverages the diversity of exosomes to design and optimize therapeutics aimed at various tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process to ensure the reproducibility and high purity of its next-generation therapeutics, enabling medical practitioners to address challenging diseases effectively.

Neurolytic Healthcare Ltd. is a medical technology company based in Oxford, United Kingdom, specializing in the design, development, and manufacture of digital and genomic-based diagnostic tools and medical devices for migraine and related neurological disorders. Founded in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnosis and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed to predict migraine events. By leveraging artificial intelligence, Neurolytic Healthcare aims to provide genomics-driven diagnostics and personalized treatment recommendations, helping patients find effective treatments while minimizing side effects and reducing the trial-and-error approach often associated with neurological care.

IDbyDNA, Inc. is a biotechnology company focused on developing metagenomics technologies for the precise identification of infectious diseases. Founded in 2014 and based in Salt Lake City, Utah, the company offers its proprietary platform, Explify, which aids laboratories in detecting pathogens through a streamlined workflow. IDbyDNA provides a range of testing services, including respiratory and research services, primarily catering to hospitals, reference labs, clinical research organizations, and the biopharmaceutical industry. By integrating computational biology and artificial intelligence into its offerings, the company enhances the accuracy of nucleic acid-based microorganism detection, enabling healthcare providers to deliver comprehensive infectious disease profiles. IDbyDNA aims to improve diagnostic and treatment practices in response to the growing challenge of infectious diseases, thereby reducing related morbidity and mortality.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Concr is a techbio company focused on enhancing cancer treatment through innovative predictive modeling. Utilizing methods derived from astrophysics, Concr aims to accurately forecast patient outcomes and responses to both novel and existing cancer therapies. The company's cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses, and conduct bioinformatics analyses, facilitating a more personalized approach to cancer care. By leveraging fragmented data from various stages of drug development, Concr eliminates the reliance on big data while generating precise multi-modal tumor models. Headquartered in London, with a subsidiary in Brisbane, Australia, Concr is backed by prominent investors, including the University of Cambridge Enterprise and Oncology Ventures, among others.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Enancio SAS, founded in 2017 and based in Cesson-Sévigné, France, specializes in developing software that focuses on genomic data compression. The company's flagship product, Lena, enhances the speed and efficiency of Next Generation Sequencing (NGS) analyses while simultaneously reducing storage costs and minimizing internal network traffic. Enancio's solutions are designed to maintain data integrity, making them a valuable addition to the genomic informatics landscape. As of July 2020, Enancio operates as a subsidiary of Illumina, Inc., thereby complementing Illumina's suite of informatics offerings.

Bluebee is a prominent provider of high-performance genomics solutions, specializing in a cloud-based platform designed for the efficient processing of large volumes of genomic data. This platform addresses the challenges faced by research and clinical laboratories in the rapidly evolving landscape of genetic analysis, particularly with the advent of next-generation DNA sequencing technology. By offering a solution that enhances data processing speed, deep analytics, and flexibility, Bluebee enables healthcare institutions to implement whole genome-based diagnostics more effectively. The company's innovative approach allows for cost-effective genetic screening, supporting the development of new diagnostics and therapies in healthcare while maintaining clinical-grade security and user convenience.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Edico Genome Inc. is a biotechnology company specializing in bioinformatics solutions for DNA analysis. Founded in 2013 and based in La Jolla, California, the company develops the DRAGEN bio-IT processor, a sequencing application-specific integrated circuit that facilitates efficient analysis of next-generation sequencing data. This platform employs a field-programmable gate array to accelerate genome pipeline algorithms, including BCL conversion, mapping, alignment, and variant calling. By integrating its technology directly into sequencing instruments and bioinformatics servers, Edico Genome enables healthcare institutions to effectively identify connections between DNA sequence variations and human diseases. In 2018, Edico Genome became a subsidiary of Illumina, Inc.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Prospect Bio is a synthetic biology company based in Brisbane, California, that specializes in developing biosensors for the detection of small molecules. These biosensors utilize living cells to perform complex chemical measurements, offering a cost-effective and scalable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. By addressing the need for improved testing solutions driven by regulatory demands, quality control, and supply chain concerns, Prospect Bio aims to transform testing processes across various industries. The company collaborates with a diverse array of partners, including major players in the wine industry, agriculture, prenatal diagnostics, and biotechnology. Its innovative approach combines microbial biotechnologies with automation and computational tools, enabling rapid biosensor and pathway discovery for medical research and other applications.

Vitagene, Inc. is a health technology company that utilizes genomic science and advanced technology to deliver personalized healthcare solutions. Founded in 2014 and based in San Francisco, the company offers a DNA-based personalization platform that helps physicians provide data-driven care. Vitagene's algorithm generates tailored supplement regimens and analyzes extensive patient data, including genetics, blood work, and lifestyle factors, to create customized nutritional plans. Additionally, the company produces DNA health test kits and at-home COVID-19 saliva test kits. It also provides comprehensive health and ancestry reports that encompass diet, exercise, and supplementation insights, ensuring that individuals receive recommendations that align with their specific health needs and goals.

Conexio Genomics, established in 2002 and headquartered in Fremantle, Australia, is a life sciences company specializing in genetic sequencing and mutation detection. It offers products such as Assign SBT and SBT Resolver for high-resolution sequencing and genotyping, and Assign-ATF for automated DNA sequence mutation detection. The company's solutions are used in various applications, including matching patients and donors for bone marrow or cord blood transplants. Conexio Genomics is currently a subsidiary of CareDx.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

GenoLogics, Inc. is a software development company that specializes in laboratory information management systems to enhance the diagnosis and treatment of diseases. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers its BaseSpace Clarity LIMS, which supports research and clinical laboratories by tracking samples throughout the testing process. This platform facilitates improved accuracy, cost reduction, and quality maintenance. The company focuses on translational medicine and systems biology, providing solutions that enable integration across multiple laboratories and enhance biomedical research efforts. As of August 2015, GenoLogics operates as a subsidiary of Illumina Inc.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

NextBio is a privately owned software company based in Cupertino, California, co-founded in 2004 by Saeid Akhtari, Ilya Kupershmidt, and Mostafa Ronaghi. The company offers a platform designed for life science researchers to efficiently search, discover, and share knowledge across both public and proprietary data. Its ontology-based semantic framework interconnects diverse data types, including gene, tissue, disease, and compound information, creating a unified searchable environment. This sophisticated platform integrates data from various organisms and research areas, enabling researchers to formulate and test hypotheses with ease. The enterprise version of NextBio's platform is utilized by prominent pharmaceutical companies such as Merck and Johnson & Johnson, allowing the integration of proprietary data with public datasets. Researchers leverage NextBio to enhance their ability to identify significant prognostic and predictive molecular signatures in their studies. The company has garnered recognition, including the Frost & Sullivan North American Life Sciences Customer Value Enhancement Award in 2008, and has attracted over 1,500,000 visitors since its launch.

Advanced Liquid Logic, Inc. is a company established in 2004 by Dr. Michael Pollack and Dr. Vamsee Pamula, who serve as co-CTOs. The company specializes in developing microfluidic devices tailored for liquid handling applications, offering innovative lab-on-a-chip solutions that can be programmed for diverse assay protocols, including immunoassays, polymerase chain reaction (PCR), clinical chemistry, and sample preparation. The team comprises a multidisciplinary group of scientists, engineers, and product developers dedicated to addressing unmet challenges in laboratories and clinics. Under the leadership of CEO Richard West, who has extensive experience in business and product development management, Advanced Liquid Logic aims to enhance workflow efficiency and effectiveness in scientific research and medical diagnostics.

Moleculo is a biotechnology company specializing in innovative DNA sequencing technologies. It has created a novel sequencing method that delivers long and accurate reads, significantly enhancing the efficiency and precision of various DNA sequencing applications. This advancement allows clients to explore a broader range of applications within genomic analysis, positioning Moleculo as a key player in the biotechnology sector focused on improving genomic tools and methodologies.

Verinata Health is a company dedicated to improving maternal and fetal health through the development of non-invasive tests designed for the early identification of fetal chromosomal abnormalities. Utilizing proprietary technologies, Verinata focuses on analyzing cell-free DNA in maternal blood to provide pregnant women with a safe, accurate, and definitive assessment of fetal aneuploidy. This approach aims to alleviate the anxiety associated with traditional multi-step prenatal screening methods, which often have high false-positive rates and can yield confusing results. By offering a single blood draw test, Verinata seeks to fulfill the recommendations for first trimester aneuploidy risk assessment, thereby enhancing the overall experience for expectant mothers. The company is actively conducting a prospective, blinded pivotal study to validate the sensitivity and specificity of its first prenatal test on a large scale, with results anticipated in the near future.

BlueGnome Limited specializes in genetic diagnostic solutions aimed at screening for chromosomal abnormalities. Founded in Fulbourn, United Kingdom, the company focuses on advancing the field of genetic testing to improve healthcare outcomes. In 2012, BlueGnome was acquired by Illumina, a leader in genomic sequencing and analysis, which allowed it to enhance its capabilities and expand its impact in the genetic diagnostics market.

GenoLogics, Inc. is a software development company that specializes in laboratory information management systems to enhance the diagnosis and treatment of diseases. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers its BaseSpace Clarity LIMS, which supports research and clinical laboratories by tracking samples throughout the testing process. This platform facilitates improved accuracy, cost reduction, and quality maintenance. The company focuses on translational medicine and systems biology, providing solutions that enable integration across multiple laboratories and enhance biomedical research efforts. As of August 2015, GenoLogics operates as a subsidiary of Illumina Inc.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.

Affomix is a biotechnology firm specializing in the development of antibody-based products, leveraging proprietary technology for the rapid and automated selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, mAb microarrays, and mAb libraries for a variety of applications, including research, drug discovery, diagnostics, and therapeutics. Affomix's innovative approach enables high-throughput production and screening of antibodies against a wide range of human proteins, including those that are post-translationally modified. This technology is particularly aimed at facilitating the sensitive and accurate measurement of numerous proteins in biological samples, thereby advancing the field of protein analysis and improving the efficacy of therapeutic solutions.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Pillar Biosciences Inc. is a biotechnology company that specializes in developing and manufacturing next-generation sequencing (NGS) assays and software for NGS laboratories. Founded in 2014 and headquartered in Natick, Massachusetts, with an additional location in Shanghai, China, Pillar Biosciences is recognized for its innovative Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology, which allows for precise priming of overlapping target segments. The company also offers PiVAT, a comprehensive bioinformatics analysis pipeline designed to enhance the accuracy of genomic data interpretation. Their targeted sequencing platform is engineered for high sensitivity and specificity, making it suitable for clinical applications, particularly in oncology. Pillar Biosciences has launched beta versions of its Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel, aimed at cancer centers and clinical testing companies for validation studies, thereby facilitating improved access to accurate genetic testing in the healthcare sector.